The Future of HIV-1 Therapeutics, 2015 Resistance Is Futile? Current Topics in Microbiology and Immunology Series, Vol. 389

This volume thoroughly covers HIV-1 antiretrovirals currently in clinical use, together with their advantages and limitations. HIV-1 inhibitor resistance is discussed in detail, and critical assessments as to what will be required of future antiretrovirals in order to halt viral replication, reduce viral resistance, and alter the state of viral latency are presented. Experts at the forefront of HIV-1 research provide overviews of approaches from the fields of virology, chemical biology and structural biology for obtaining small molecule inhibitors that target viral regulatory and structural components at multiple points in the viral lifecycle. The individual chapters will appeal to scientists and clinicians alike.

HIV Therapy ­ Looking Towards the Future

David Looney, Ariel Ma, and Scott Johns

Computational challenges of structure-based approaches applied to HIV

Stefano Forli and Arthur J. Olson

Nucleocapsid Protein: A Desirable Target For Future Therapies Against HIV-1

Mattia Mori, Lesia Kovalenko, Sébastien Lyonnais, Danny Antaki, Bruce E. Torbett, Maurizio Botta, Gilles Mirambeau, and Yves Mély

HIV-1 integrase multimerization as a therapeutic target

Lei Feng, Ross Larue, Jacques J. Kessl, and Mamuka Kvaratskhelia

Targeting HIV transcription: The quest for a functional cure

Guillaume Mousseau, Sonia Mediouni, and Susana T. Valente

Targeting the HIV RNA Genome: High-Hanging Fruit Only Needs a Longer Ladder

Stuart F.J. Le Grice

HIV-1 Gag: An Emerging Target for Antiretroviral Therapy

Philip R. Tedbury and Eric O. Freed

The Triple Threat of HIV-1 Protease Inhibitors

Marc Potempa, Sook-Kyung Lee, Richard Wolfenden, and Ronald Swanstrom

Illustrations of the HIV Life Cycle

David S. Goodsell

Highlights the identification and evaluation of antiretrovirals that may be less prone in selecting for HIV-1 resistance

Covers recent advances in the identification and function of small molecule inhibitors that target novel HIV-1 regulatory and structural components to disrupt replication and alter the state of viral latency

Offers up-to-date information for virologists, infectious disease specialists, and chemical biologists on HIV-1 antiretrovirals currently in use

Includes supplementary material: sn.pub/extras